Skip to main content Back to Top


Teprotumumab-trbw Injection

Reason for the Shortage

    • Horizon Therapeutics had Tepezza on back order because the manufacturing facility is being used to make COVID-19 vaccine. Additional information can be found at or

Available Products

    • Tepezza intravenous lyophilized powder for injection, Horizon Therapeutics, 500 mg, single dose vial, 1 count, NDC 75987-0130-15

Estimated Resupply Dates

    • Horizon Therapeutics has Tepezza available.


Updated April 12, 2021 by Michelle Wheeler, PharmD, Drug Information Specialist. Created February 10, 2021 by Leslie Jensen, PharmD, Drug Information Specialist. © 2021, Drug Information Service, University of Utah, Salt Lake City, UT.


Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.